Corbus Pharmaceuticals Holdings, Inc. Common Stock CRBP
i
Market datapartial · fetched 2026-11-13T19:12:07.704Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T19:10:32.379018781Z
FundamentalsAlpha Vantage · unavailable
Corbus Pharmaceuticals Holdings, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 3.98 | 247.7% | 23.9% | |||
| 45Δ | 3.71 | 297.7% | 23.0% | |||
| 50Δ | 3.44 | 347.7% | 22.2% | |||
| 55Δ | 3.17 | 397.7% | 21.3% | |||
| 60Δ | 2.90 | 447.7% | 20.5% | |||
| 65Δ | 2.63 | 497.7% | 19.6% | |||
| 70Δ | 2.36 | 547.6% | 18.8% | 4.29 | 213.3% | 4.7% |
| 75Δ | 2.09 | 597.6% | 17.9% | 4.69 | 243.6% | 4.1% |
| 80Δ | 1.82 | 647.6% | 17.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 3.98
- IV
- 247.7%
- B/E move
- 23.9%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 3.71
- IV
- 297.7%
- B/E move
- 23.0%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 3.44
- IV
- 347.7%
- B/E move
- 22.2%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 3.17
- IV
- 397.7%
- B/E move
- 21.3%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 2.90
- IV
- 447.7%
- B/E move
- 20.5%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 2.63
- IV
- 497.7%
- B/E move
- 19.6%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 2.36
- IV
- 547.6%
- B/E move
- 18.8%
- Pseudo strike
- 4.29
- IV
- 213.3%
- B/E move
- 4.7%
75Δ
- Pseudo strike
- 2.09
- IV
- 597.6%
- B/E move
- 17.9%
- Pseudo strike
- 4.69
- IV
- 243.6%
- B/E move
- 4.1%
80Δ
- Pseudo strike
- 1.82
- IV
- 647.6%
- B/E move
- 17.1%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
CRBU
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies…
More →CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
More →CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in…
More →CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug,…
More →CRVS
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is…
More →CTMX
Description unavailable
More →